Literature DB >> 9589405

Isolation and quantification of fluoroacetate in rat tissues, following dosing of Z-Phe-Ala-CH2-F, a peptidyl fluoromethyl ketone protease inhibitor.

T H Eichhold1, E B Hookfin, Y O Taiwo, B De, K R Wehmeyer.   

Abstract

Peptidyl fluoromethyl ketones (PFMK) are irreversible inhibitors of cathepsin B, a cysteine proteinase thought to be involved in the degradation of cartilage. It has been speculated that PFMK inhibitors may metabolize in rodents to form fluoroacetate (FAC), an extremely toxic poison. A highly selective and sensitive separation and detection scheme was developed to measure trace levels of FAC in rat tissues following PFMK dosing. The procedure consisted of extracting FAC from tissue and spiking the extract with [18O]2-fluoroacetate (18O-FAC) as an internal standard. FAC and 18O-FAC were further isolated from matrix components using ion-exchange, solid-phase extraction. The pentafluorobenzyl esters of FAC and 18O-FAC were formed to facilitate the chromatographic separation. Two-dimensional gas chromatography coupled with selected-ion-monitoring detection provided the final measurement. The assay had a limit of detection of 2 ng FAC per g tissue, and was capable of accurately quantitating as little as 10 ng FAC per g tissue with a S/N ratio of 40:1. Linearity was established over two orders of magnitude, from 2-500 ng ml-1, with 5 microliters injected on-column. The method was used to demonstrate that FAC was formed in rats following dosing with Z-Phe-Ala-CH2-F, a PFMK cathepsin enzyme inhibitor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9589405     DOI: 10.1016/s0731-7085(97)00102-7

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  7 in total

Review 1.  Experimentally promising antischistosomal drugs: a review of some drug candidates not reaching the clinical use.

Authors:  Rashad A Abdul-Ghani; Naguiba Loutfy; Azza Hassan
Journal:  Parasitol Res       Date:  2009-07-09       Impact factor: 2.289

2.  Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor.

Authors:  Maha-Hamadien Abdulla; Kee-Chong Lim; Mohammed Sajid; James H McKerrow; Conor R Caffrey
Journal:  PLoS Med       Date:  2007-01       Impact factor: 11.069

Review 3.  Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors.

Authors:  Marton Siklos; Manel BenAissa; Gregory R J Thatcher
Journal:  Acta Pharm Sin B       Date:  2015-09-26       Impact factor: 11.413

4.  Caspase vinyl sulfone small molecule inhibitors prevent axonal degeneration in human neurons and reverse cognitive impairment in Caspase-6-overexpressing mice.

Authors:  Prateep Pakavathkumar; Anastasia Noël; Clotilde Lecrux; Agne Tubeleviciute-Aydin; Edith Hamel; Jan-Eric Ahlfors; Andrea C LeBlanc
Journal:  Mol Neurodegener       Date:  2017-02-28       Impact factor: 14.195

Review 5.  Current Synthetic Routes to Peptidyl Mono-Fluoromethyl Ketones (FMKs) and Their Applications.

Authors:  Carissa M Lloyd; Neil Colgin; Steven L Cobb
Journal:  Molecules       Date:  2020-11-28       Impact factor: 4.411

6.  Off-target inhibition of NGLY1 by the polycaspase inhibitor Z-VAD-fmk induces cellular autophagy.

Authors:  Sarah H Needs; Martin D Bootman; Jeff E Grotzke; Holger B Kramer; Sarah A Allman
Journal:  FEBS J       Date:  2022-01-18       Impact factor: 5.622

7.  Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection.

Authors:  J C Engel; P S Doyle; I Hsieh; J H McKerrow
Journal:  J Exp Med       Date:  1998-08-17       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.